neratinib
knight therapeutics,puma,pierre fabre
['neratinib', 'puma']
 2022 updates:
at the ongoing #asco 2022 conference, puma biotechnology showcased the final results from the phase ii basket trial of #neratinib for her2+ biliary tract cancer. for more details, visit #asco #asco22 #asco2022 #oncology #oncologist 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry